AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17165348
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) 0.02 mg/kg
Trial: 29683914
Drug: Daily undulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily undulating periodization (UP)
Trial: 21636319
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin treatment guided by EMG
Trial: 21636319
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin treatment based on clinical judgement alone
Trial: 7992901
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (0.4 mg.kg-1 bolus followed by 30 micrograms.kg-1.min-1)
Trial: 7992901
Drug: Clonidine (3-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (3-4 micrograms.kg-1 oral)
Trial: 7992901
Drug: Nasal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal lidocaine (2 ml of 4% spray)
Trial: 2608700
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg pessary
Trial: 4219401
Drug: 1.5% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% amino acid solution with 10% carbohydrates (sorbitol, xylitol)
Trial: 4219401
Drug: Conventional basic
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional basic electrolyte solution
Trial: 24127346
Drug: Intravenous aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous aflibercept 2 mg/kg
Trial: 24127346
Drug: Intravenous aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous aflibercept 4 mg/kg
Trial: 15573736
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride at 1-2 mg/kg
Trial: 9849445
Drug: Erythropoietin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (200 U/kg body weight daily)
Trial: 2048592
Drug: 50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 micrograms ethinyl estradiol and 1.0 mg norethindrone
Trial: 2048592
Drug: 35 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 micrograms ethinyl estradiol and 1.0 mg norethindrone
Trial: 2048592
Drug: Type O
RxNorm normalized name: Yersinia enterocolitica type O:3 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type O women using the highest estrogen dose preparation (50 micrograms)
Trial: 2048592
Drug: Non-type O
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-type O women using the lowest progestin dose preparation (0.5 mg)
Trial: 25212456
Drug: Deferasirox treatment
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferasirox treatment for iron overload
Trial: 12092634
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E)
Trial: 9632125
Drug: Behavioural group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural group therapy
Trial: 8291731
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg intravenous (2 ml) ketorolac, followed by 30 mg intravenously (in saline 20 ml) over 30 min every 6 h
Trial: 8291731
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml intravenous saline, followed by saline 20 ml intravenously over 30 min every 6 h
Trial: 23744953
Drug: Subcostal TAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcostal TAP block (group TAP) with 20 mL of 0.375% ropivacaine
Trial: 23744953
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural analgesia (group EA) with 8 mL of 0.25% ropivacaine before induction and maintained with 5 mL/h of 0.25% ropivacaine
Trial: 14559046
Drug: Manual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual treatment (MT group)
Trial: 10762020
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Tamoxifen and Fenretinide (4-HPR)
Trial: 8955967
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 0.025 mg.kg‐1
Trial: 8955967
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 0.050 mg.kg‐1
Trial: 8955967
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 0.050-0.150 mg.kg‐1
Trial: 27823869
Drug: Mavoglurant 25
RxNorm normalized name: Mavoglurant
DrugBank: Mavoglurant (DB13004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavoglurant 25 mg
Trial: 27823869
Drug: Mavoglurant 50
RxNorm normalized name: Mavoglurant
DrugBank: Mavoglurant (DB13004)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mavoglurant 50 mg
Trial: 27823869
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg (oral)
Trial: 22963754
Drug: 1% tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% tetracaine gel
Trial: 22963754
Drug: 1% tetracaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% tetracaine solution
Trial: 21064010
Drug: Procaine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine infusion (1% solution, 8 ml/h, 1.92 g/24 h)
Trial: 21064010
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion (0.9% saline solution)
Trial: 14745070
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (1,500 mg daily)
Trial: 12193977
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg warfarin daily
Trial: 12193977
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg warfarin daily
Trial: 12193977
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg warfarin daily
Trial: 12193977
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg phenprocoumon daily
Trial: 12193977
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg phenprocoumon daily
Trial: 2594898
Drug: Diazepam (DZ)
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam (DZ) 40 or 80 mg
Trial: 2594898
Drug: Triazolam (TZ)
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triazolam (TZ) 1.0 or 2.0 mg
Trial: 28474866
Drug: Gymnastics training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gymnastics training (G)
Trial: 27680484
Drug: Fentanyl 30
RxNorm normalized name: fentaNYL 300 mcg oral lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 30 μg/mL
Trial: 27680484
Drug: Fentanyl 15
RxNorm normalized name: fentaNYL 150 mcg/30 mL-D5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 15 μg/mL
Trial: 23523674
Drug: Immediate pegylated
RxNorm normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate pegylated interferon alfa-2b treatment for 24 weeks
Trial: 23523674
Drug: Delayed pegylated
RxNorm normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed pegylated interferon alfa-2b plus ribavirin treatment starting 12 weeks after randomisation if HCV RNA remained positive
Trial: 23523674
Drug: Delayed pegylated
RxNorm normalized name: antihemophilic factor (recombinant) pegylated Injection [Adynovate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed pegylated interferon alfa-2b plus ribavirin treatment
Trial: 23523674
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (symptomatic or asymptomatic)
Trial: 23523674
Drug: Asymptomatic patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asymptomatic patients receiving immediate treatment
Trial: 9538651
Drug: Streptokinase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase treatment (Group 2)
Trial: 9538651
Drug: No streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No streptokinase treatment (Group 1)
Trial: 1493087
Drug: Trimethoprim (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim (150 mg)
Trial: 1493087
Drug: Trimethoprim-sulphamethoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulphamethoxazole (160 and 800 mg)
Trial: 3895099
Drug: Intensive cyclic
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive cyclic therapy (using drugs like AMSA, 5-AZA, and HD-araC) during remission induction.
Trial: 3895099
Drug: Maintenance arm
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance arm I (specific drugs not detailed).
Trial: 3895099
Drug: Maintenance arm
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance arm II (specific drugs not detailed).
Trial: 31012052
Drug: Red blood
RxNorm normalized name: Red blood cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red blood cell (RBC) transfusion at a hemoglobin level of ≤ 70 g·L–1 in the acute phase of care
Trial: 31012052
Drug: Red blood
RxNorm normalized name: Red blood cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red blood cell (RBC) transfusion at a hemoglobin level of ≤ 70 g·L–1 in the plateau phase of care
Trial: 27629292
Drug: Once-monthly paliperidone
RxNorm normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once-monthly paliperidone palmitate (PP)
Trial: 27629292
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral antipsychotics (COAs)
Trial: 27629292
Drug: Atypical oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical oral antipsychotics (AOAs)
Trial: 27629292
Drug: Oral paliperidone/risperidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paliperidone/risperidone
Trial: 16552830
Drug: continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuation of preceding Kampo prescription
Trial: 10821985
Drug: Oral cotinine
RxNorm normalized name: Chinine
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cotinine
Trial: 1311794
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 B‐estradiol (TTS 50; 50 mcg/day)
Trial: 1311794
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 B‐estradiol (TTS 50; 50 mcg/day) + Vaginal progesterone (P4; 100 mg twice daily)
Trial: 25421475
Drug: ACT-451840 200
RxNorm normalized name: ACT-451840
DrugBank: ACT-451840 (DB13054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-451840 200 mg
Trial: 25421475
Drug: ACT-451840 500
RxNorm normalized name: ACT-451840
DrugBank: ACT-451840 (DB13054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-451840 500 mg
Trial: 25421475
Drug: ACT-451840 500
RxNorm normalized name: ACT-451840
DrugBank: ACT-451840 (DB13054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-451840 500 mg with food
Trial: 25421475
Drug: ACT-451840 200
RxNorm normalized name: ACT-451840
DrugBank: ACT-451840 (DB13054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-451840 200 mg and 500 mg
Trial: 22526973
Drug: Laser dissection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser dissection (L)
Trial: 16837887
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (CEE) 0.625 mg daily and 2.5 mg of medroxyprogesterone acetate daily
Trial: 16837887
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol (TE2) 50 mcg twice weekly and 2.5 mg of medroxyprogesterone acetate daily
Trial: 14992985
Drug: Pramipexole (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (mean maximum dose=1.7 mg/day, SD=1.3)
Trial: 11376503
Drug: Microstream capnometer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microstream capnometer (NBP‐75, Nellcor Puritan Bennett) with an aspiration flow rate of 30 ml.min‐1
Trial: 11376503
Drug: Conventional sidestream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional sidestream capnometer with a 200 ml.min‐1 aspiration flow rate
Trial: 8111816
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day nifedipine
Trial: 8111816
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day nifedipine
Trial: 8111816
Drug: 90 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg/day nifedipine
Trial: 22488107
Drug: Pentosan Polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan Polysulfate Sodium (PPS), single oral dose
Trial: 22488107
Drug: Pentosan Polysulfate
RxNorm normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentosan Polysulfate Sodium (PPS), daily oral doses for 8 weeks
Trial: 22488107
Drug: Heparin, lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin, lower doses than used for anticoagulation
Trial: 20829712
Drug: ACEi (enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEi (enalapril 20 mg/day) during high salt (200 mmol Na/day)
Trial: 20829712
Drug: ACEi (enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEi (enalapril 20 mg/day) during low salt (50 mmol Na/day)
Trial: 16988909
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g protein (14 g whey and casein protein, 6 g free amino acids)
Trial: 16988909
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g dextrose placebo
Trial: 10435264
Drug: Alcohol self-administration
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol self-administration study with naltrexone
Trial: 7381649
Drug: 43 microgram
RxNorm normalized name: gonadorelin
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 43 microgram HA vaccine
Trial: 7381649
Drug: 10 microgram
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microgram HA vaccine
Trial: 7381649
Drug: 4 microgram
RxNorm normalized name: Paricalcitol 4 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 microgram HA vaccine
Trial: 17944013
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of epinephrine (5 mg each)
Trial: 17944013
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of epinephrine (1 mg each)
Trial: 15172463
Drug: Intracoronary beta-radiation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary beta-radiation therapy (ICR)
Trial: 7574814
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy combined with hyperthermia
Trial: 7574814
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy alone
Trial: 387498
Drug: Oral trithiozine
RxNorm normalized name: anethole trithione
DrugBank: Anethole trithione (DB13853)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trithiozine
Trial: 26514065
Drug: Short-term psychodynamic
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term psychodynamic group therapy (20 weekly sessions)
Trial: 26514065
Drug: Long-term psychodynamic
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term psychodynamic group therapy (80 weekly sessions)
Trial: 21369479
Drug: HA/CMC injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA/CMC injection
Trial: 15475635
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose hepatitis B vaccine (2 mcg) given intradermally
Trial: 15475635
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose hepatitis B vaccine (10 mcg) given intramuscularly
Trial: 7577849
Drug: Gestrinone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestrinone (2.5 mg twice weekly)
Trial: 20211501
Drug: Multidimensional exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidimensional exercise (twice a week for 3 months)
Trial: 17962426
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of 150 mg lamivudine, 300 mg zidovudine, and 200 mg nevirapine
Trial: 17962426
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination and individual products
Trial: 11211891
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha 2b 3 MU tiw for 24 or 48 weeks plus ribavirin 1000‐1200 mg
Trial: 9510317
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg mesalazine suppositories administered three times per day
Trial: 9510317
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg oral mesalazine tablets taken three times per day
Trial: 26987935
Drug: Very low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Very low-dose factor VIII prophylaxis (10 units kg(‐1) body weight on 2 days a week)
Trial: 26987935
Drug: Episodic (On
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Episodic (On demand) factor concentrate in standard recommended doses
Trial: 26987935
Drug: Very low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Very low-dose factor VIII prophylaxis
Trial: 1488696
Drug: Rice-powder salt
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice-powder salt solution (RPSS) - 30 g/l rice powder and 3.5 g/l salt
Trial: 1488696
Drug: WHO recommended
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [WHO Recommended Hand Rub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO recommended glucose electrolyte solution (WHO-ORS)
Trial: 1488696
Drug: Glycine supplemented
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine supplemented WHO-ORS (G-ORS)
Trial: 3566222
Drug: Lysozyme in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysozyme in combination with antibiotics
Trial: 3566222
Drug: Antibiotics without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotics without lysozyme
Trial: 26833752
Drug: 1000 U/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 U/mL heparin (low dose)
Trial: 26833752
Drug: 5000 U/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 U/mL heparin (high dose)
Trial: 22921260
Drug: Nabilone 1-4
RxNorm normalized name: nabilone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone 1-4 mg/day (n=13)
Trial: 20805256
Drug: Continuous antidepressant
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous antidepressant use in the placebo arm
Trial: 20805256
Drug: Continuous antidepressant
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous antidepressant use in the lifestyle arm
Trial: 20805256
Drug: Continuous antidepressant
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous antidepressant use in the metformin arm
Trial: 16197668
Drug: Cyclobenzaprine 5
RxNorm normalized name: cyclobenzaprine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine 5 mg TID for 7 days (CYC5)